APP Insight: Evaluating Time to Response and Treatment Effectiveness
GHAPPcast25 Syys 2025

APP Insight: Evaluating Time to Response and Treatment Effectiveness

Thank you to Ardelyx for your support on this APP Insight video module.

In this video, physician assistant Kim Orleck of Atlanta Gastroenterology Associates, part of United Digestive, answers some of the most common questions about IBS medications and how to evaluate treatment success. Kim explains how clinical studies show bowel improvement—measured by complete spontaneous bowel movements—can often begin as early as one week, sometimes even within days, while abdominal pain relief typically takes 6–8 weeks to reach maximal benefit. She emphasizes the importance of setting realistic expectations so patients don’t discontinue therapy too soon. With no current biomarkers for IBS, Kim highlights how progress is assessed by carefully tracking the patient’s response across constipation, abdominal pain, and bloating symptoms. She also shares best practices on when to reassess therapy—usually at the 2–3 month mark—to ensure both bowel and pain improvements are achieved. This discussion offers valuable guidance for clinicians and patients navigating the complexities of irritable bowel syndrome (IBS-C) management.

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(154)

Medication Review: Guselkumab IV vs SC Formulation

Medication Review: Guselkumab IV vs SC Formulation

Thank you to Johnson & Johnson for their support on this Medication Review Video Module. In this quick educational video, Angelina Collins, NP, from the University of California San Diego Inflammatory...

28 Touko 3min

FAQ: Recognizing OHE Risk in Patients with Chronic Liver Disease

FAQ: Recognizing OHE Risk in Patients with Chronic Liver Disease

Thank you to Salix for the support on this FAQ Video Module.This educational FAQ module, featuring Mikhail Alper, PA-C focuses on recognizing risk factors and early clinical indicators of Overt Hepati...

26 Touko 2min

FAQ: Phase 3 GALAXI 2 & 3: Extraintestinal Manifestations In Moderate to Severe Crohn’s Disease

FAQ: Phase 3 GALAXI 2 & 3: Extraintestinal Manifestations In Moderate to Severe Crohn’s Disease

Thank you to Johnson & Johnson for the support on this FAQ Video Module.This FAQ video features Janette Villalon, PA, who reviews the role of guselkumab in treating extraintestinal manifestations in p...

19 Touko 5min

Medication Review: Monotherapy vs. Combination Therapy: Relevance in IBD Treatment Strategy

Medication Review: Monotherapy vs. Combination Therapy: Relevance in IBD Treatment Strategy

Thank you to Celltrion for the support on this Medication Review Video Module.This medication review explores the evolving role of monotherapy versus combination therapy in the treatment of inflammato...

14 Touko 3min

Medication Review: Stable PK Supporting Continuous Inflammatory Control

Medication Review: Stable PK Supporting Continuous Inflammatory Control

Thank you to Celltrion for the support on this Medication Review Video Module.This medication review explores the role of stable pharmacokinetics (PK) in achieving continuous inflammatory control in i...

7 Touko 6min

Journal Club: ASTRO Phase 3 Study: Efficacy and Safety of SC Guselkumab

Journal Club: ASTRO Phase 3 Study: Efficacy and Safety of SC Guselkumab

Thank you to Johnson & Johnson for the support on this Journal Club Review Module.In this journal club video, Sharon Dudley Brown, CRNP, PhD, from the IBD Center at Johns Hopkins University, reviews t...

28 Huhti 5min

Journal Club: Benefit–Risk Profile of Upadacitinib in Patient’s With Moderate to Severe UC and CD

Journal Club: Benefit–Risk Profile of Upadacitinib in Patient’s With Moderate to Severe UC and CD

Thank you to AbbVie for the support on this Journal Club Review Module.This journal club review episode explores the benefit–risk profile of Upadacitinib for patients with moderately to severely activ...

21 Huhti 23min

Podcast: How Do You Best Support Patients Getting Started on New MASH Treatments?

Podcast: How Do You Best Support Patients Getting Started on New MASH Treatments?

Learn how to effectively support patients starting treatment for MASH with this practical, clinician-focused discussion featuring expert advanced practice providers. In this episode, hepatology specia...

14 Huhti 18min

Suosittua kategoriassa Terveys ja hyvinvointi

unicast
psykopodiaa-podcast
rss-pitaisko-erota
tiedenaiset-podcast
vakeva-elama-viisaampi-mieli-vahvempi-keho
voi-hyvin-meditaatiot-2
rss-narsisti
rss-kuumilla-aalloilla
puhu-muru
rss-uplevel-by-sonja-hannus
katilon-kahvitunti
meditaatiot-suomeksi
terapiassa
rss-nautinto
traumapodi
rss-terapiaklubi
monisuhteellista
fitnessvastaanotto
rss-palaudu-synnytyksesta-podcast
rss-hereilla